leisure time -WSS

leisure time

author：comprehensive 2025-09-06 03:53:07 - browse：986

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Medical student insurance fails on mental health care coverage

WSS

How AI helped researchers track recovery from depression

Intarcia’s device

Weight loss drugs should be covered by insurers, AMA says

Microbiome research is starting to find links to chronic diseases

Second xenotransplant done with gene

CVS, Rite Aid closures threaten to worsen pharmacy deserts

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Heart attack and stroke risk calculators need revising

Type 2 diabetes prevention programs work at large scale: study

Alkermes shareholders re

First transplant of an entire human eye performed

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Second xenotransplant done with gene

Hepatitis C has a cure — but many Americans still lack access to it

Weight loss drugs should be covered by insurers, AMA says

Malaria cases in Florida and Texas: Here’s what you need to know

Weight loss drugs should be covered by insurers, AMA says

focus

It's been 20 years since Dolly the sheep. Where's my clone?

Publishing genetic code of viruses could cause disaster

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Healthy food access boosts outcomes in two studies

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Experts study whether long Covid risk adds up with each reinfection

leisure time

explore

hotspot

hotspot